AB Science is developing two main compounds Masitinib and AB8939

Annual financial results as of 31 December, 2020

April 30, 2021

30/04/2021 – AB Science reports its annual financial results as of 31 December, 2020

Masitinib Phase 2B/3 study in prostate cancer met its primary endpoint

April 29, 2021

29/04/2021 – AB Science today announces that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint

AB Science secures 6M€ in non-dilutive financing guaranteed by the French Government

April 14, 2021

14/04/2021 – AB Science today announces that it has received financing approval from Société Générale, Bpifrance and Banque Populaire for a total of EUR 6 million in the form of state-guaranteed loans

Signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19

April 6, 2021

06/04/2021 – AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19

Update on masitinib Phase 3 study in prostate cancer

March 31, 2021

31/03/2021 – AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer

A new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders

March 8, 2021

08/03/2021 – AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders including Alzheimer’s Disease

positive phase 2B/3 readouts with masitinib

publications in peer-reviewed journals

patients enrolled in masitinib studies